Here’s what you need to know:
1. Exalenz Bioscience has developed the BreathID System, a noninvasive breath-based medical device that diagnoses and monitors gastrointestinal and liver diseases by detecting the presence of H. pylori bacteria.
2. Conatus Pharmaceuticals is investigating emricasan, a compound that Conatus developed to treat patients with chronic liver disease.
3. In Conatus’ IIb clinical trial of emricasan, researchers will use BreathID to monitor patients with nonalcoholic fatty liver disease cirrhosis.
4. For this trial, Exalenz Bioscience received FDA approval for an investigational device exemption.
5. At present, there are no noninvasive diagnostic methods to diagnose or monitor NASH. The only available methods are invasive liver biopsy and hepatic venous pressure gradient.
More articles on gastroenterology and endoscopy:
Who is Donald Trump’s gastroenterologist, Dr. Harold Bornstein?: 5 things to know
Takeda announces Access to Medicines strategy: 5 notes
Vitality Biopharma announces new patent filing for IBD pain relief: 4 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.